Skip to content

Study · Non-randomized trial · n = 11 · 2007

9 results

Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes.

Ghofaili KA, Fung M, Ao Z, Meloche M, Shapiro RJ, Warnock GL, Elahi D, Meneilly GS, Thompson DM

Transplantation1 Jan 2007Cited by 91 (Europe PMC)

PMID17220786 (opens in a new tab)DOI10.1097/01.tp.0000251379.46596.2d (opens in a new tab)PepBankPUB-17220786
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In islet transplant recipients with elevated glucose, ten patients responded to exenatide.

    In plain wordsTen islet transplant recipients responded to exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableTreatment response
    Study

    n = 11

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Measurements

    Responders
    10 patients
    responders to exenatide

    Source sentences

    Summary
    Ten patients responded to exenatide.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  2. 02HumanNon-randomized trialEfficacy outcome

    In seven islet recipients, insulin dose decreased during exenatide treatment.

    In plain wordsSeven islet recipients needed less insulin during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin dose
    Study

    n = 7

    Comparator
    Before exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Measurements

    Insulin dose reduction
    39%
    seven patients

    Source sentences

    Summary
    Seven other patients decreased their insulin dose by 39% on exenatide.
    2 context sentences
    Summary · context
    Ten patients responded to exenatide.
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  3. 03HumanNon-randomized trialEfficacy outcome

    In islet recipients who had not restarted insulin, two patients achieved good glycemic control with exenatide.

    In plain wordsTwo islet recipients who had not restarted insulin achieved good glucose control with exenatide.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGlycemic control without restarting insulin
    Study

    n = 2

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Measurements

    Patients with good glycemic control without restarting insulin
    2 patients
    not restarted insulin

    Source sentences

    Summary
    Two patients who had not restarted insulin achieved good glycemic control and one patient who had received 5500 IE/kg in first islet infusion was able to stop insulin.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  4. 04HumanNon-randomized trialEfficacy outcome

    In one islet recipient, insulin was stopped during exenatide treatment.

    In plain wordsOne islet recipient could stop insulin during exenatide treatment.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseInsulin cessation
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Measurements

    Patients able to stop insulin
    1 patients
    exenatide treatment

    Source sentences

    Summary
    Two patients who had not restarted insulin achieved good glycemic control and one patient who had received 5500 IE/kg in first islet infusion was able to stop insulin.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  5. 05HumanNon-randomized trialEfficacy outcome

    In islet recipients, second-phase insulin release increased during exenatide treatment in hyperglycemic clamp tests.

    In plain wordsIslet recipients released more insulin during exenatide treatment than before treatment in glucose clamp tests.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseSecond-phase insulin release
    Study

    n: not reported in source

    Comparator
    Before exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Measurements

    Second-phase insulin release
    246 pM
    before exenatide
    Second-phase insulin release
    644 pM
    during exenatide

    Source sentences

    Summary
    Hyperglycemic clamp studies showed a rise in second phase insulin release (before exenatide: 246+/-88 pM; during exenatide: 644+/-294 pM, P<0.01).
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  6. 06HumanNon-randomized trialEfficacy outcome

    In islet recipients, meal-test glucose did not differ before treatment versus one month after stopping exenatide.

    In plain wordsMeal-test glucose was similar before exenatide and one month after stopping it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMeal tolerance glucose after withdrawal
    Study

    n: not reported in source

    Comparator
    Before exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Meal tolerance studies before and one month after stopping exenatide did not show a difference in glucose or C-peptide values.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  7. 07HumanNon-randomized trialEfficacy outcome

    In islet recipients, meal-test C-peptide did not differ before treatment versus one month after stopping exenatide.

    In plain wordsMeal-test C-peptide was similar before exenatide and one month after stopping it.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeMeal tolerance C-peptide after withdrawal
    Study

    n: not reported in source

    Comparator
    Before exenatide
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Meal tolerance studies before and one month after stopping exenatide did not show a difference in glucose or C-peptide values.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  8. 08HumanNon-randomized trialSafety outcome

    In islet recipients receiving exenatide, nausea was a major side effect.

    In plain wordsNausea was a major exenatide side effect in islet recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedNausea
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Nausea and vomiting were the major side effects.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.
  9. 09HumanNon-randomized trialSafety outcome

    In islet recipients receiving exenatide, vomiting was a major side effect.

    In plain wordsVomiting was a major exenatide side effect in islet recipients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Direction not reportedVomiting
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · three monthsAs given in this study (human).

    Source sentences

    Summary
    Nausea and vomiting were the major side effects.
    1 context sentence
    Summary · context
    Eleven C-peptide positive islet cell recipients with elevated glucose levels were treated with exenatide for three months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.